Clinical trials have historically required in-person attendance for participants. As the onset of the COVID-19 pandemic impacted the practicality to continue the traditional clinical trial format, researchers began exploring modifications to keep clinical trials open through telehealth and local collection of laboratory tests or imaging studies. While the implementation of telehealth in clinical trials proved successful in several research spaces, its feasibility and safety had yet to be fully explored in cancer populations.
To better understand the safety of telehealth in oncologic clinical trials, researchers led by PC3I Faculty Emily Ko, MD, MSCR evaluated gynecologic oncology patients who were enrolled in clinical trials during the COVID-19 pandemic. Patients in remote clinical trials were assessed for adverse health outcomes, emergency department visits, and hospital admissions and compared to those in traditional clinical trial settings.
Findings published in Gynecologic Oncology showed no difference in adverse patient outcomes between the two groups, demonstrating that telehealth and remote testing are safe to implement in clinical trials. Telehealth did not impact clinical trial protocols, and should be considered for larger scale clinical trial adaptation in oncology settings. Further suggestions include the need for increased flexibility in clinical trial design and more inclusion of telehealth in clinical trials to decentralize operations. Additionally, since Medicare’s pandemic emergency coverage is set to end in December of 2024, considerations of telehealth reimbursement should be made.
Learn more about this project.
PC3I and Tennessee Oncology’s McKay Institute for Oncology Transformation Unveil New Collaborative Relationship
PC3I and Tennessee Oncology’s McKay Institute for Oncology Transformation announce an academic-community oncology innovation partnership to improve cancer care delivery.
PC3I Associate Director Surbhi Grover and Deputy Director Katharine Rendle presented research at the 14th AORTIC International Conference on Cancer in Africa, which took place in Dakar, Senegal.
Through the Innovation Accelerator, the Penn Center for Cancer Care Innovation (PC3I) at the Abramson Cancer Center (ACC) invite applications for initiatives that aim to create and test innovative solutions to address challenges in productivity, efficiency, clinician wellbeing, or access in cancer care at Penn Medicine